The FDA actively – and unusually – collaborated with a biopharmaceutical company to pursue the approval of an Alzheimer's Disease drug, despite many questions about its efficacy and astronomical price. A congressional investigation found that the FDA’s approval process was “rife with irregularities" and that the agency’s actions “raise serious concerns about FDA’s lapses in protocol.”
Biomedicine & Biotech
If you're sick and tired of hearing about yet another Omicron subvariant taking over the world you're not alone. But there is one subvariant called Centaurus, aka B.27.5, that provides a fascinating example of how a seemingly-minuscule mutation can have a profound effect on the virus. And, at no extra cost, a Dreaded Chemistry Lesson From Hell! Plus a gratuitous shot at Dr. Oz.
On episode 8 of the Science Dispatch Podcast, we examine recent claims about the efficacy of Paxlovid. Is the COVID-19 drug as effective as experts thought it'd be? We then debunk an Epoch Times story alleging that the weedkiller glyphosate is lurking in every corner, just waiting to poison you and your children.
A recent study showed that Pfizer's Paxlovid, the most effective Covid drug, failed to prevent infection when given to people who were exposed to the virus but had not yet become infected. Bad news, right? Actually, no - it's quite the opposite. Here's why.
Canada has approved Medicago's plant-based COVID-19 vaccine. The new shot itself is an impressive development, but the technology it's built on suggests that we may be growing more drugs in greenhouses in the coming years.
There’s considerable discussion about whether COVID vaccines are responsible for the barrage of variants that keep hitting us. Is selective pressure driving this – like with bacteria and antibiotics? Let's take a look.
The same mRNA technology that gave us effective COVID-19 vaccines could yield a new generation of highly protective seasonal flu shots. When will we see these upgraded influenza vaccines? Perhaps sooner than you think.
Several superficially plausible arguments against COVID-19 vaccination continue to pop up across the internet, usually phrased as leading questions. Are they as solid as they seem? A little investigation suggests they are mostly speculation.
Research has shown that adverse events following COVID-19 vaccination are very rare. Another large study of VAERS reports strengthens this conclusion.
Just what we need: another COVID variant. This one is called Delta AY.4.2 and it's now circulating in the UK. It might be a bit worse than the already awful Delta variant. Should we be concerned? And what does this suggest about COVID in the future?
Emergency Use Authorization (EUA) from the FDA is the exception, not the rule. Except for COVID therapies. Three vaccines and one drug have EUA in the US. Merck is now seeking EUA for its antiviral drug molnupiravir. Should it be granted?
Dr. David Shlaes has been following the various discussions around the development of rapid diagnostic tests for acute bacterial infections. The ACSH advisor has concluded that broad-spectrum empiric therapy of potentially serious infections in the hospital will continue – and well it should – regardless of the availability of such rapid tests.